Michelle Bucaria - Teladoc Chief Human Resource Officer
| TDOC Stock | USD 11.43 0.06 0.53% |
Insider
Michelle Bucaria is Chief Human Resource Officer of Teladoc since 2018.
| Age | 48 |
| Tenure | 6 years |
| Address | 2 Manhattanville Road, Purchase, NY, United States, 10577 |
| Phone | 203 635 2002 |
| Web | https://www.teladochealth.com |
Michelle Bucaria Latest Insider Activity
Tracking and analyzing the buying and selling activities of Michelle Bucaria against Teladoc stock is an integral part of due diligence when investing in Teladoc. Michelle Bucaria insider activity provides valuable insight into whether Teladoc is net buyers or sellers over its current business cycle. Note, Teladoc insiders must abide by specific rules, including filing SEC forms every time they buy or sell Teladoc'sshares to prevent insider trading or benefiting illegally from material non-public information that their positions give them access to.
Michelle Bucaria over three months ago Disposition of 12782 shares by Michelle Bucaria of Jamf Holding at 15.2515 subject to Rule 16b-3 | ||
Michelle Bucaria over three months ago Disposition of 12782 shares by Michelle Bucaria of Jamf Holding at 15.2515 subject to Rule 16b-3 | ||
Michelle Bucaria over three months ago Disposition of 24282 shares by Michelle Bucaria of Jamf Holding at 15.4533 subject to Rule 16b-3 |
Teladoc Management Efficiency
The company has return on total asset (ROA) of (0.0313) % which means that it has lost $0.0313 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.5165) %, meaning that it created substantial loss on money invested by shareholders. Teladoc's management efficiency ratios could be used to measure how well Teladoc manages its routine affairs as well as how well it operates its assets and liabilities. As of November 29, 2024, Return On Tangible Assets is expected to decline to -0.14. The current year's Return On Capital Employed is expected to grow to -0.06. At present, Teladoc's Non Current Assets Total are projected to increase significantly based on the last few years of reporting. The current year's Non Currrent Assets Other is expected to grow to about 84.3 M, whereas Net Tangible Assets are projected to grow to (475.5 M).Similar Executives
| Showing other executives | INSIDER Age | ||
| Nicolette Sherman | Certara | 54 | |
| Jon Maack | Definitive Healthcare Corp | N/A | |
| Jim Grauel | FOXO Technologies | N/A | |
| Daniel Tan | EUDA Health Holdings | 43 | |
| Steven Sobak | EUDA Health Holdings | 78 | |
| Michael Gill | Healthcare Triangle | 46 | |
| Gregory MS | National Research Corp | N/A | |
| Jon Boumstein | National Research Corp | N/A | |
| Suresh Venkatachari | Healthcare Triangle | 57 | |
| Kate Jensen | Definitive Healthcare Corp | 38 | |
| Andrew Schemick | Certara | 50 | |
| Lakshmanan Kannappan | Healthcare Triangle | 57 | |
| David Kronfeld | Definitive Healthcare Corp | N/A | |
| Justin Steinman | Definitive Healthcare Corp | N/A | |
| Joseph Mirisola | Definitive Healthcare Corp | 40 | |
| John Lorbiecki | Aclarion | 61 | |
| Scott Oberlink | Definitive Healthcare Corp | N/A | |
| Brian Chen | FOXO Technologies | N/A | |
| Jaap Mandema | Certara | N/A | |
| Jona Raasch | National Research Corp | 65 | |
| Robert JD | Definitive Healthcare Corp | 54 | |
Management Performance
| Return On Equity | -0.52 | ||||
| Return On Asset | -0.0313 |
Teladoc Leadership Team
Elected by the shareholders, the Teladoc's board of directors comprises two types of representatives: Teladoc inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Teladoc. The board's role is to monitor Teladoc's management team and ensure that shareholders' interests are well served. Teladoc's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Teladoc's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Mike Waters, Chief Officer | ||
| Andrew Turitz, Senior Vice President of Corporate Development | ||
| Catherine Jacobson, Independent Director | ||
| Sandra Fenwick, Independent Director | ||
| Joseph Cpa, Senior Officer | ||
| Michelle Bucaria, Chief Human Resource Officer | ||
| Christopher Bischoff, Independent Director | ||
| David Shedlarz, Independent Director | ||
| William Frist, Independent Director | ||
| Mala Murthy, Chief Financial Officer | ||
| Mark Smith, Independent Director | ||
| CPA III, CEO Director | ||
| David Snow, Independent Chairman of the Board | ||
| David Sides, Chief Operating Officer | ||
| Richard Napolitano, Senior Vice President Chief Accounting Officer | ||
| Nikolaos Nanis, Chief Officer | ||
| Thomas McKinley, Independent Director | ||
| Karen Daniel, Independent Director | ||
| Lewis Levy, Chief Medical Officer | ||
| Claus Jensen, Chief Officer | ||
| Daniel Trencher, Senior Vice President - Corporate Strategy | ||
| Adam Vandervoort, Chief Legal Officer and Secretary | ||
| Arnnon Geshuri, Chief Human Resource Officer | ||
| Adam JD, Chief Secretary | ||
| Stephany Verstraete, Chief Officer | ||
| Laizer Kornwasser, President Markets | ||
| Gabriel Cappucci, Senior Vice President Chief Accounting Officer, Controller | ||
| Yulun Wang, Head of Research and Development | ||
| Kenneth Paulus, Independent Director | ||
| Stephanie Verstraete, Chief Marketing Officer | ||
| George Brooks, CoFounder | ||
| Hemant Taneja, Director | ||
| Glen Tullman, Director | ||
| CPA CFA, Vice Relations | ||
| Jason Gorevic, Chief Executive Officer, Director | ||
| Courtney McLeod, Director Communication | ||
| Peter McClennen, Independent Director | ||
| Michael Waters, Chief Officer | ||
| Carlos Nueno, President International |
Teladoc Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Teladoc a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.52 | ||||
| Return On Asset | -0.0313 | ||||
| Profit Margin | (0.38) % | ||||
| Operating Margin | (0.06) % | ||||
| Current Valuation | 2.31 B | ||||
| Shares Outstanding | 172.17 M | ||||
| Shares Owned By Insiders | 0.80 % | ||||
| Shares Owned By Institutions | 77.23 % | ||||
| Number Of Shares Shorted | 25.69 M | ||||
| Price To Earning | (21.84) X |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether Teladoc offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Teladoc's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Teladoc Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Teladoc Stock:Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Teladoc. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in persons. For information on how to trade Teladoc Stock refer to our How to Trade Teladoc Stock guide.You can also try the Portfolio Suggestion module to get suggestions outside of your existing asset allocation including your own model portfolios.
Is Health Care Technology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Teladoc. If investors know Teladoc will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Teladoc listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (5.78) | Revenue Per Share 15.333 | Quarterly Revenue Growth (0.03) | Return On Assets (0.03) | Return On Equity (0.52) |
The market value of Teladoc is measured differently than its book value, which is the value of Teladoc that is recorded on the company's balance sheet. Investors also form their own opinion of Teladoc's value that differs from its market value or its book value, called intrinsic value, which is Teladoc's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Teladoc's market value can be influenced by many factors that don't directly affect Teladoc's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Teladoc's value and its price as these two are different measures arrived at by different means. Investors typically determine if Teladoc is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Teladoc's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.